News

The Pharma Letter47m
Revenues flat at Gilead as HIV strength offsets oncology struggle
Gilead Sciences (Nasdaq: GILD) reported flat revenues for the first quarter of 2025, with total sales reaching $6.7 billion, ...
The Pharma Letter1h
FDA approves penpulimab-kcqx for NP carcinoma
The US Food and Drug Administration (FDA) approved penpulimab-kcqx, from little known Chinese biotech Akeso Biopharma (HKEX: ...